Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HBB | P68871 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | PNP | P00491 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8760981 | 0.84 | MEN1 (0.49) | MEN1KMT2AHBBMAPK1BLM | |
| SCHEMBL8760993 | 0.80 | MEN1 (0.43) | MEN1KMT2AHBBMAPK1BLM | |
| SCHEMBL7627167 | 0.79 | PNP (0.58) | MEN1KMT2AHBBMAPK1BLM | |
| SCHEMBL6834577 | 0.76 | PNP (0.56) | MEN1KMT2AHBBMAPK1BLM | |
| SCHEMBL3857906 | 0.75 | HPRT1 (0.66) | PNPHPRT1 | |
| SCHEMBL20997456 | 0.75 | PNP (0.55) | MEN1KMT2AHBBMAPK1BLM | |
| SCHEMBL8760975 | 0.75 | PNP (0.45) | MEN1KMT2AHBBMAPK1BLM | |
| SCHEMBL17194164 | 0.74 | HPRT1 (0.52) | MEN1KMT2AHBBMAPK1BLM | |
| SCHEMBL6266779 | 0.74 | TK1 (0.58) | MEN1KMT2AHBBBLMPNP | |
| SCHEMBL3857910 | 0.74 | HPRT1 (0.53) | MEN1KMT2AHBBBLMPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | AVENTIS PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | claimed |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | CASARA PATRICK (FR) | 2003-01-02 | — | — | US | claimed |
| US-5922696-A | VIRICIDES AGAINST DNA VIRUSES, RETROVIRUSES AND VIRUSES INVOLVED IN TUMOR FORMATION, CYTOMEGALOVIRUS, VARICELLA-ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HUMAN IMMUNODEFICIENCY VIRUSES | MERRELL PHARMACEUTICALS INC. (US) | 1999-07-13 | — | — | US | claimed |
| EP-0701562-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | claimed |
| WO-1994022882-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | claimed |
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | AVENTIS PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | CASARA PATRICK (FR) | 2003-01-02 | — | — | US | disclosed |
| US-5922696-A | VIRICIDES AGAINST DNA VIRUSES, RETROVIRUSES AND VIRUSES INVOLVED IN TUMOR FORMATION, CYTOMEGALOVIRUS, VARICELLA-ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HUMAN IMMUNODEFICIENCY VIRUSES | MERRELL PHARMACEUTICALS INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5817647-A | VIRICIDES; ANTITUMOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0701562-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994022882-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | MEN1 4298/4885KMT2A 4278/4885HBB 4370/4885 |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | MEN1 4298/4885KMT2A 4278/4885HBB 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.